Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 3
Submit an article Journal homepage
51
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Intravenous iron therapy for patients with iron deficiency and heart failure: a systematic review and meta-analysis of randomized controlled trials

Mohammed Mhannaa Division of Cardiology, Department of Medicine, University of Iowa, Iowa City, IA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1443-7177
, MD, MPHORCID Icon,
Michael C. Sauerb Department of Medicine, University of Iowa, Iowa City, IA, USA
, MD,
Ahmad Al-Abdouhc Department of Internal Medicine, University of Kentucky, Lexington, KY, USA
, MD,
Ahmad Jabrid Department of Cardiology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH, USA
, MD,
Azizullah Berane Department of Gastroenterology, Indiana University, Indianapolis, IN, USA
, MD,
Mahmoud Barbarawif Department of Cardiology, University of Connecticut, Farmington, CT, USA
, MD,
Shareef Mansoura Division of Cardiology, Department of Medicine, University of Iowa, Iowa City, IA, USA
, MBBS &
Elias B. Hannaa Division of Cardiology, Department of Medicine, University of Iowa, Iowa City, IA, USA
, MD show all
Pages 466-476 | Received 25 Aug 2023, Accepted 19 Feb 2024, Published online: 21 Mar 2024

  • McMurray JJ, Stewart S. The burden of heart failure. Eur Heart J Suppl. 2002;4(suppl_D):D50–D58. doi:10.1016/S1520-765X(02)90160-4.
  • von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019;7(1):36–46. doi:10.1016/j.jchf.2018.07.015.
  • Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Iron deficiency in heart failure. ESC Heart Fail. 2021;8(4):2368–2379. doi:10.1002/ehf2.13265.
  • Alnuwaysir RI, Hoes MF, van Veldhuisen DJ, van der Meer P, Grote Beverborg N. Iron deficiency in heart failure: mechanisms and pathophysiology. J Clin Med. 2022;11(1):125. doi:10.3390/jcm11010125.
  • Graham FJ, Pellicori P, Ford I, Petrie MC, Kalra PR, Cleland JGF. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clin Res Cardiol. 2021;110(8):1299–1307. doi:10.1007/s00392-021-01837-8.
  • Zhang S, Zhang F, Du M, Huang K, Wang C. Efficacy and safety of iron supplementation in patients with heart failure and iron deficiency: a meta-analysis. Br J Nutr. 2019;121(8):841–848. doi:10.1017/S000711451900014X.
  • Osman M, Syed M, Balla S, Kheiri B, Faisaluddin M, Bianco C. A meta-analysis of intravenous iron therapy for patients with iron deficiency and heart failure. Am J Cardiol. 2021;141:152–153. doi:10.1016/j.amjcard.2020.11.025.
  • Ponikowski P, Kirwan B-A, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895–1904. doi:10.1016/S0140-6736(20)32339-4.
  • Kalra PR, Cleland JG, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199–2209. doi:10.1016/S0140-6736(22)02083-9.
  • Mentz RJ, Garg J, Rockhold FW, et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 2023;389(11):975–986. doi:10.1056/NEJMoa2304968.
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
  • Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–1805. doi:10.1177/0962280216669183.
  • Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.4. Cochrane; 2023. www.training.cochrane.org/handbook.
  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557.
  • Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–613. doi:10.1016/S0140-6736(98)01085-X.
  • Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–2448. doi:10.1056/NEJMoa0908355.
  • Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168(4):3439–3442. doi:10.1016/j.ijcard.2013.04.181.
  • Dhoot S, Mittal S, Singh SP, Patel V, Kasliwal RR, Mehta V. Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency. Future Sci OA. 2020;6(5):FSO467. doi:10.2144/fsoa-2019-0156.
  • Marcusohn E, Borreda I, Hellman Y, et al. IV Sodium ferric gluconate complex in patients with iron deficiency hospitalized due to acute heart failure—investigator initiated, randomized controlled trial. J Cardiovasc Pharmacol. 2022;80(2):194–196. doi:10.1097/FJC.0000000000001287.
  • Martens P, Dupont M, Dauw J, et al. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial. Eur Heart J. 2021;42(48):4905–4914. doi:10.1093/eurheartj/ehab411.
  • Núñez J, Miñana G, Cardells I, et al. Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the Myocardial‐IRON trial. J Am Heart Assoc. 2020;9(4):e014254. doi:10.1161/JAHA.119.014254.
  • Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency: FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103–112. doi:10.1016/j.jacc.2007.09.036.
  • Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668. doi:10.1093/eurheartj/ehu385.
  • Toblli JE, Di Gennaro FP. Long-term effect of intravenous iron on overall survival and hospitalization in patients with heart failure with reduced ejection fraction, iron deficiency and mild renal impairment: an open-label 5-year follow up observation. J Clin Diagn Res. 2017;11(11):OC18-OC24.
  • van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136(15):1374–1383. doi:10.1161/CIRCULATIONAHA.117.027497.
  • Yeo TJ, Yeo PSD, Hadi FA, et al. Single‐dose intravenous iron in Southeast Asian heart failure patients: a pilot randomized placebo‐controlled study (PRACTICE‐ASIA‐HF). ESC Heart Fail. 2018;5(2):344–353. doi:10.1002/ehf2.12250.
  • Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80–98. doi:10.1161/CIRCULATIONAHA.118.030099.
  • Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232–2237. doi:10.1093/eurheartj/ehi388.
  • Haas JD, Brownlie IVT. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. 2001;131(2S-2):676S–690S. doi:10.1093/jn/131.2.676S.
  • Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35(7):1737–1744. doi:10.1016/s0735-1097(00)00613-6.
  • Sawicki KT, Ardehali H. Intravenous iron therapy in heart failure with reduced ejection fraction: tackling the deficiency. Circulation. 2021;144(4):253–255. doi:10.1161/CIRCULATIONAHA.121.054271.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.